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Oral Presentations 19activity regulated by Killer Immunoglobulin Receptor (KIR) genes
may tip the balance towards either detrimental or beneficial out-
comes. Both recipients and donors of 605 first allogeneic non-T de-
pleted transplants were retrospectively KIR genotyped. In the non-
HLA identical transplants, 92 inhibitory KIR ligand (iKIRL) mis-
matched cases displayed the worst five-year overall survival (OS,
20%) perhaps due to higher non-relapse mortality. In contrast,
75 transplants with only an HLA class-I antigen (Ag) incompatibil-
ity, but without an iKIRL incompatibility had significantly better
OS (41%, p\0.001), which was similar to that (39%) of the Class
I allele mismatched transplants, suggesting that incompatible
iKIRLs exacerbated the effect of HLA Class I mismatches. In the
HLA identical cases, the presence of both patient and donor
2DL/S2 resulted in a better OS (72% vs 58%, p\0.01) due to
less relapse. Interestingly, the impact was concentrated in HLA-
Cw iKIRL group 1 homozygotes. The absence of 2DL/S2 in the re-
cipients decreased OS by 20% (72% vs 52%, p\0.001). The effect
was not observed in the 10/10 (HLA-A, B, C, DRB1, DQB1)
matched transplant cases, suggesting that, NK cell activity in
HCT recipients, may be beneficial when the alloimmune response
is less stimulated. Our study reflects the diversified role of NK cells
inHCT, and suggests that KIR genotypingmay be useful in clinical
practice.IMMUNE RECONSTITUTION
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MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY TO PREVENT OR
TREAT INFECTIONS OF STEM CELL TRANSPLANT RECIPIENTS
Gerdemann, U.1, Christin, A.1, Fujita, Y.1, Vera, J.F.1, Ramos, C.A.1,
Dilloo, D.2, Brenner, M.K.1, Heslop, H.E.1, Rooney, C.M.1,
Leen, A.M.1 1Center for Cell and Gene Therapy, Baylor College of Med-
icine, Methodist Hospital and Texas Children’s Hospital, Houston, TX;
2Clinic for Pediatric Oncology, Heinrich Heine University of Duesseldorf,
Duesseldorf, Germany
Viral infections cause morbidity and mortality in allogeneic
HSCT recipients. To treat the underlying problem, namely lack
of antigen-specific T cells, we and others have successfully gener-
ated and infused adoptive T-cell lines specific for EBV, CMV and
Adenovirus. We have shown that as few as 2  105/kg trivirus-
specific cytotoxic T lymphocytes (CTL) proliferated by several
logs post-infusion and appeared to protect the recipients against
all three viruses. Despite the encouraging clinical results, broader
implementation of the approach is limited by (i) the usage of infec-
tious virus material (EBV/Adv) and (ii) the prolonged culture (3
months for EBV-LCL production and CTL stimulation). Finally,
(iii) ‘‘antigenic competition’’ between multiple viral antigens
limits the extension to additional viruses. To overcome these
limitations we have developed an approach to rapidly produce
multivirus-specific CTL without using adenoviral vectors or
EBV-LCL. Using nucleofection we consistently detected GFP
transgene expression of 39% of transfected DCs, without ad-
versely affecting cell viability or DC maturation status. Coculture
of p-Shuttle-pp65-GFP-transfected DCs with PBMCs from
CMV seropositive individuals reactivated CMV-specific T-cells,
which were detectable 9 days after stimulation, at higher frequen-
cies (as measured by g-IFNELIspot and Pentamer analysis (HLA-
A2, NLV)) than lines generated using our standard protocol with
Ad5f35pp65-transduced DCs as APCs. Importantly, this protocol
could also be used to reactivate T cells against multiple viruses.
Using a panel of p-Shuttle plasmids encoding LMP2 and
BZLF1 (EBV), Large T (BK), and Hexon and Penton (Adv), we
amplified CTLs from seropositive donors specific for the different
viruses. Furthermore, we demonstrated that by pooling trans-
fected DCs prior to PBMC stimulation, we could reproducibly
generate multivirus-specific CTL lines, specific for all the stimu-
lating antigens, without observing antigenic competition. To
shorten the CTL production process, we established the selection
of highly virus-specific T cells by IFN-g capture 24 hours after
DC stimulation. In summary, we have established two GMP-ap-
plicable protocols for the rapid generation (\10 days) of CTL
without using infectious material. In 10 days we can generatemono- or multivirus -specific CTL lines for prophylactic applica-
tion. By performing IFN-g selection we can rapidly generate
virus-specific CTLs for treatment of acute infection.45
DONOR LYMPHOCYTE INFUSIONS DEPLETED OF ALLOREACTIVE T CELLS
DECREASE INFECTIONS WITHOUT CAUSING GVHD AFTER HAPLOTYPE
MISMATCHED MYELOABLATIVE STEM CELL TRANSPLANTATION
Roy, D.-C.1, Cohen, S.1, Busque, L.1, Fish, D.1, Kiss, T.1, Lachance, S.1,
Sauvageau, G.1, Rovers, J.2, Roy, J.1 1Hopital Maisonneuve-Rosemont,
Montreal, QC, Canada; 2Kiadis Pharma, Amsterdam, Netherlands
The ability to accelerate immune reconstitution following
haplo-mismatched stem cell transplantion (SCT) would limit in-
fections and disease relapse, and provide a unique opportunity to
transplant the large number of patients who cannot find an HLA-
matched donor. We present results of a Phase I clinical trial of
haplo-mismatched allogeneic SCT supplemented with a donor
lymphocyte infusion (DLI) photodynamically depleted of host-re-
active T cells using dibromorhodamine as photosensitizer and
visible light illumination (512 nm) (ATIR-PDT, Kiadis Pharma).
Nineteen patients (11 M, 8 F) with high-risk hematologic malig-
nancies (mostly refractory or relapsed acute myeloid leukemia
(10) and myelodysplastic syndromes (4)) entered the trial. Median
age at SCT was 54 years (range: 19–62). Increasing doses of
PDT-treated donor cells (1  104 to 5.0  106 CD31 cells/kg)
were administered on day 34 6 6 after transplant. Greater than
95% of anti-host cytotoxic T lymphocyte precursors (CTLp)
were depleted from DLIs. All stem cell grafts underwent in vitro
immunomagnetic T cell depletion using CD341 positive cell se-
lection (Miltenyi). The myeloablative regimen consisted of TBI
(1200 cGy), thiotepa (5 mg/kg) and fludarabine (40 mg/m2/day
for 5 days) followed by infusion of CD3 depleted hematopoietic
stem cell grafts. No GVHD prophylaxis was administered. All pa-
tients showed complete donor chimerism and durable hemato-
logic engraftment. No patient developed acute GVHD (grade
II-IV). Eight patients died: 4 of relapsed leukemia (3 AML; 1
ALL) and 4 of infections, all after day1300. In the first 7 patients
who received 1.3  105 or less CD31 cells/kg, 11 infectious ep-
isodes (4 lethal) occurred in these 7 pts (100% of pts). In sharp
contrast, only 5 infectious episodes (none lethal) were observed
in 3 (27%) of the following 11 patients receiving DLI with the
highest doses of CD31 cells (3.2  105 to 5.0  106 CD31
cells/kg) (p \0.05). Chronic GVHD developed in 5 patients,
mostly in those receiving higher T cell doses, and responded rap-
idly to steroid-based immunesuppression. The overall survival is
67% at 2 years (median follow-up: 10.5 mo). Our results indicate
that the post-transplant infusion of an ATIR-PDT treated DLI is
feasible, does not induce acute GVHD, and suggests a clinical
benefit for patients receiving the highest DLI doses to accelerate
T cell reconstitution.46
RAPID RECOVERY OF ABSOLUTE LYMPHOCYTE COUNTS (ALC) IS PRE-
DICTIVE OF FAVORABLE OUTCOMES FOLLOWING UMBILICAL CORD
BLOOD (UCB) TRANSPLANTATION: IMPACT OF THE USE OF TWO UCB
UNITS
Verneris, M.R., Janardan, S., Isaksson, R., Brunstein, C.G.,
Weisdorf, D.J., Miller, J.S., Wagner, J.E. University of Minnesota,
Minneapolis, Mn
After UCB transplantation, neutrophil recovery is markedly
slower than other stem cell sources. The kinetics of lymphocyte re-
covery and their significance has not been extensively evaluated.
We analyzed the maximumweekly ALC based on total white count
and automated differential. To assess the impact of ALC on
transplant outcomes, we analyzed 80 consecutive AML patients
transplanted with UCB after a myeloablative conditioning from
2001–6. Six patients with graft failure or early death were excluded,
resulting in 74 (92.5%) evaluable patients. The median age was
21.4 yrs (range 0.5–43.9). The majority of patients (85.1%) re-
ceived cyclophosphamide (60mg/kg x 2), fludarabine (75mg/m2)
20 Oral Presentationsand 13.2 cGy TBI. GVHD prophylaxis was with CSA/MMF.
Thirty two percent were transplanted with one UCB unit and
68% with two units. Disease status at the time of transplant in-
cluded: CR1 (46%), CR2 (45%), .CR2-relapse (9%). Sixty one
percent of patients are alive at a median follow up of 737 days
(range 44–2,322 days). Using survival tree and log rank analysis,
weekly ALCs were analyzed to determine an ALC cut-point which
gave two distinct groups based on transplant associated outcomes.
In multivariate analysis an ALC . 0.2  109/L at 4 weeks after
UCB transplant was associated with significantly better disease
free survival (DFS) (relative risk (RR) 5 0.158, 69% vs. 33%,
p 5 0.0005) and overall survival (OS) at 2 years (RR 5 0.125,
74% vs. 33%, p\0.0001). Similarly, at this same cut off (ALC .
0.2), patients were less likely to have treatment related mortality
(TRM) (RR 5 0.01, 7% vs. 67%, p\0.0001). For grade II-IV
aGVHD, multivariate analysis showed that an ALC . 0.4 (at 4
weeks post-transplant) was associated with less aGVHD at
D1100 (RR 5 0.057, 28% vs. 61%, p 5 0.0004). At 7 weeks after
transplant, patients with an ALC . 1.2 109/liter was associated
with a lower risk of relapse (univariate analysis 0% vs. 21%, p 5
0.026). We next sought to determine whether any factor predicted
better ALC recovery at four weeks post-UCB transplant. Multi-
variate analysis revealed that the only factor associated with
more rapid ALC recovery was the use of two umbilical cord blood
units. Double unit recipients had an ALC that was10.155 109/L
higher at 4 weeks compared to single unit recipients (p 5 0.039).
Collectively, these data suggest that ALC is a readily available
parameter for assessing risks for TRM, DFS, OS and relapse.
Rapid ALC recovery may explain the observed benefits with
double UCB transplant.LATE EFFECTS/QUALITY OF LIFE
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THE IMPACT OF FULL DOSE TOTAL BODY IRRADIATION(TBI)-CONTAIN-
ING CONDITIONING ON CHRONIC KIDNEY DISEASE AND THROMBOTIC
MICROANGIOPATHIC ANEMIA IN ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION(HSCT)
Glezerman, I.1, Jhaveri, K.2, Papadopouolos, E.B.1, Flombaum, C.1,
Jakubowski, A.A.1 1Memorial Sloan Kettering Cancer Center,
New York, NY; 2Weill Medical College of Cornell University, New
York, NY
Background: Chronic kidney disease (CKD) and thrombotic mi-
croangiopathy (TMA) are potential late post-transplant complica-
tions in survivors of HSCT. CKD and TMA can have a significant
impact on healthcare costs and quality of life. Both disorders have
been associated with calcineurin inhibitors (CNI), TBI, older age, fe-
male gender, and graft versus host disease (GVHD), however, the
contribution of each of these factors on development of CKD/
TMAhas not beenwell defined.T-cell depletion (TCD) of allografts
as prophylaxis for GvHD has produced similar survival outcomes to
those of conventional HSCTs in appropriately selected patients and
can obviate the need for CNIs. The lack of CNI exposure offers
a unique opportunity to study the role of TBI in the development
of CKD/TMA.
Methods: Between 1/2001 and 1/2005, 102 adult patients re-
ceived TCD myeloablative HSCTs at MSKCC and met inclusion
criteria for this analysis which was approved by the IRB. Thirty-
two patients received a non-TBI containing regimen (group A) and
70 received TBI (1375 cGy without kidney shielding) with chemo-
therapy (groupB). Baseline and followup data were collected by a ret-
rospective review of medical records. Renal function (estimated
glomerular filtration rate [GFR]) was calculated using the Modified
Diet in Renal Disease extended equation. TMA was diagnosed by
kidney biopsy or by identification of multiple components of the
clinical syndrome.
Results: Median followup for both groups was 21months. Results
and incidence of CKD and TMA are summarized below. Of note,
pretransplant GFR was lower in group A vs B (p\0.006). Incidence
of CKD, TMA, and HTN was significantly higher in those patients
receiving TBI (group B).Conclusions: The data demonstrate a strong correlation between
the use of TBI, in the absence of CNIs, and the development of post-
transplant CKD and TMA, suggesting the need for clinical trials to
prevent these complications when using TBI.Group A Group B P\Pre-treatment GFR1 (mean) 87.1 (SD525.6) 102.3 (SD523.9) 0.006
GFR at 6 months (mean) 72.3 (SD521.9) 74.8 (SD522.6) NS (0.6)
GFR at 12 months (mean) 67.2 (SD514.1) 61.6 (SD519.8) NS (0.13)
GFR at 18 months (mean) 67.9 (SD510.2) 59.8 (SD520.5) 0.02
GFR at 24 months (mean) 68.3 (SD512.3) 60.5 (SD522.0) 0.05
TMA2 0 (0%) 11 (15.7%) 0.016
HTN3 2 (6.3%) 18 (25.7%) 0.02
GFR\30 at 24 months 0 (0%) 6 (10.9%) 0.171Glomerular filtration rate.
2Thombotic microangiopathic anemia.
3Hypertension.48
RELAPSE AND MORTALITY IN YOUNG SURVIVORS 2.5 YEARS AFTER AU-
TOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR SOLID ORGAN TUMORS AND MALIGNANT BLOOD
DISORDERS
Hutspardol, S., Shaw, P.J. The Children’s Hospital AtWestmead, Sydney,
New South Wales, Australia
We studied the mortality, relapse and transplant-related compli-
cations of 331 patients (age 6 month–19 years at transplant, median
8 years) with solid organ tumors (91 soft-tissue tumor and 18 brain
tumor) and malignant blood disorders (200 leukemia and 22
lymphoma) after a bone marrow (n 5 265), peripheral blood (n 5
56), and cord blood (n 5 10) hematopoietic stem cell transplant
(HSCT). One hundred and forty-six patients remained relapse-free
for 2.5 or more years after HSCT. Of these, 132 (90%) were alive
at a median follow up time of 10 years (range; 2.5–27.0). Four
(2.7%) relapsed between 2.7 and 13.4 years (median 6.1) after trans-
plant. No patients with hematologic malignancies relapsed after 2.5
years of HSCT. Six patients (4.1%) died of complications related to
the transplant: 3 from chronic pulmonary graft-versus-host disease
and 1 each from presumed busulphan-induced chronic obstructive
lung disease, cardiomyopathy, and non-GVHD interstitial
pulmonary fibrosis. Three patients (2.1%) developed T-cell ALL,
rhabdomyosarcoma and astrocytoma as second malignancies. For
the external cause of death, one died from drug overdose at 5 years
after the transplant. The 5- and 10-year probabilities of overall sur-
vival (from the 2.5-year mark) are 95% and 93% and the 5- and 10-
year probabilities of relapse free survival (from the 2.5-year mark) are
98% and 95%. In multivariate analysis, peripheral blood stem cell
(PBSC) as the source of stem cells and older age at HSCT unfavor-
ably influenced the overall survival. Gender, age at HSCT, type of
malignant disease, low or high risk category for relapse, stem cell
source and TBI were not found to be predictive for relapse free sur-
vival. In conclusion, for young patients with malignancies who were
relapse free 2.5 years after HSCT, the probability of cure was very
high and the long term survival was excellent. Chronic pulmonary
GVHD was the leading cause of late death. Toxicity related to
high intensity chemotherapy and TBI potentially resulted to the
lung toxicity and death in long term survivors.49
MEASURING THE SYMPTOM BURDEN OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN PATIENTS WITH AND WITHOUT
ACUTE GRAFT-VERSUS-HOST DISEASE
Williams, L.A.1, Giralt, S.A.2, Wang, X.S.1, Mobley, G.M.1,
Mendoza, T.R.1, Cohen, M.Z.3, Cleeland, C.S.1 1The University of Texas
M.D. Anderson Cancer Center, Houston, TX; 2The University of Texas
M.D. Anderson Cancer Center, Houston, TX; 3University of Nebraska
Medical Center, Omaha, NE
Significance: Allogeneic hematopoietic stem cell transplantation
(alloHSCT) is an intensive but potentially curative therapy for
patients with life-threatening illnesses. During alloHSCT, patients
